What Schedule III Rescheduling Changes for Cannabis—and What It Does Not

280E Tax Relief: The Immediate Financial Impact

Schedule III rescheduling would allow state-licensed cannabis businesses to deduct ordinary business expenses under federal tax law, ending the application of IRC Section 280E. Under current Schedule I classification, cannabis operators can't deduct rent, payroll, or operating costs. Effective tax rates exceed 70 percent in some cases. Multi-state operators including Curaleaf, Trulieve, and Green Thumb Industries reported combined 280E-related tax burdens exceeding $1.2 billion in fiscal year 2025, according to earnings disclosures filed with the SEC.

The tax change applies only to businesses compliant with state licensing frameworks. It doesn't extend to unlicensed cultivation or distribution. Treasury guidance issued in March 2026 clarified that rescheduling alone doesn't create a safe harbor for operators violating state possession limits or diversion controls.

Effective dates remain uncertain. The DEA's notice of proposed rulemaking, published in May 2024, triggered a comment period that closed in July 2024. No final rule has been issued. Industry analysts project a final rule in Q4 2026 at the earliest, with tax relief taking effect in the tax year following publication.

Criminal Law: Federal Penalties Remain Intact

Rescheduling to Schedule III doesn't decriminalize cannabis under the Controlled Substances Act and preserves federal criminal penalties for unauthorized manufacture, distribution, and possession. Schedule III substances including ketamine, anabolic steroids, and Tylenol with codeine remain subject to DEA registration requirements and criminal enforcement outside approved medical channels.

DOJ hasn't issued updated enforcement guidance. The Cole Memorandum, rescinded in January 2018, previously deprioritized federal prosecution of state-compliant operators. No equivalent memo has been reinstated. U.S. Attorneys retain full discretion to prosecute CSA violations in states with legal markets, and they've shown willingness to use it when diversion or interstate trafficking surfaces.

Federal employees, contractors, and security-clearance holders face unchanged employment restrictions. The Office of Personnel Management confirmed in August 2026 that Schedule III classification doesn't alter federal workplace drug policies or create exemptions for state-legal use. For comprehensive background on the rescheduling process and timeline, see the CannIntel topic hub on DEA Schedule III rescheduling.

Research and FDA Pathways: Expanded but Narrow

Schedule III status reduces DEA barriers to cannabis research by eliminating Schedule I registration requirements, but FDA approval remains mandatory for any therapeutic claim or interstate commerce. Universities and private research entities would no longer require special DEA Schedule I facility licenses, a process that historically added 12 to 18 months and costs exceeding $100,000 per site, according to a 2025 NIH survey of institutional review boards.

The change doesn't authorize over-the-counter sales. It doesn't create a federal medical cannabis program. State-licensed dispensaries operate entirely outside FDA jurisdiction. Any product making therapeutic claims or crossing state lines requires New Drug Application approval, a pathway no cannabis product has completed. Epidiolex, the only FDA-approved cannabis-derived drug, underwent Phase III trials costing an estimated $300 million before approval in June 2018.

The DEA's proposed rule doesn't address the NIDA monopoly on federally legal research-grade cannabis. The agency's contract with the University of Mississippi, renewed in 2020, remains in effect. Researchers have criticized NIDA-supplied material as unrepresentative of commercial products in potency and cannabinoid profile.

State Programs and Banking: No Federal Safe Harbor

Schedule III rescheduling doesn't preempt state law or create federal authorization for state-licensed cannabis commerce, leaving operators exposed to asset forfeiture and banking restrictions under the Bank Secrecy Act. The Controlled Substances Act prohibits distribution of Schedule III substances without DEA registration. No state-licensed dispensary holds such registration. Federal law doesn't recognize state medical or adult-use frameworks as compliant distribution channels.

The SAFE Banking Act, which would prohibit federal regulators from penalizing financial institutions serving state-legal cannabis businesses, hasn't passed. Rescheduling doesn't alter Bank Secrecy Act requirements or FinCEN guidance mandating suspicious activity reports for cannabis-related transactions. Most federally insured banks continue to refuse accounts for plant-touching businesses.

What comes next? Final rule publication in the Federal Register, which triggers a 60-day effective date under the Administrative Procedure Act. Until that publication, Schedule I classification remains in force.